News about "Glenmark"

NPPA Fixes Retail Prices for 11 Drug Formulations Under DPCO 2013

The National Pharmaceutical Pricing Authority (NPPA) has issued a fresh notification fixing retail prices for multiple essential drug formulations—including antihypertensives, antibiotics, antidiabetics, and paediatric syrups—under the Drugs (Prices Control) Order, 2013. The revised prices apply to approved manufacturers and exclude GST.

Glenmark | 02/12/2025 | By Dineshwori

Glenmark Pharmaceuticals Receives EIR from US FDA for Monroe Facility

Glenmark Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US FDA for its formulations manufacturing facility in Monroe, with a Voluntary Action Indicated (VAI) status.

Glenmark | 27/11/2025 | By Dineshwori |  116

Glenmark Launches New Fixed-Dose Triple Therapy for COPD

The treatment combines three medications—an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA)—into a single inhaler, aiming to simplify therapy and improve patient adherence.

Glenmark | 26/11/2025 | By Darshana |  104

Indian Pharmaceutical Alliance Welcomes New Leadership

Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, and Vice President, Indian Pharmaceutical Alliance (IPA), has been appointed President of the alliance, while Glenn Saldanha, Chairman and Managing Director, Glenmark, will serve as the new Vice President.

Glenmark | 04/10/2025 | By Dineshwori |  139

Glenmark Secures USD 1.0 Billion Licensing Deal for Next-Gen Cancer Drug with Chinese Partner

Under the terms of the deal, Glenmark will make an upfront payment of USD 18 million and may pay up to USD 1.093 billion in regulatory and commercial milestone payments, in addition to royalties tied to future sales.

Glenmark | 25/09/2025 | By Darshana |  133

Cosmo and Glenmark Receive UK MHRA Approval of Winlevi for Treatment of Acne

Winlevi® is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.

Glenmark | 10/02/2025 | By Aishwarya |  380

Glenmark Rolls Out Travoprost Ophthalmic Solution

Glenmark’s Travoprost Ophthalmic Solution USP, 0.004 percent is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004 percent of Sandoz, Inc.

Glenmark | 27/11/2024 | By Aishwarya |  220

Glenmark Gets ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules

Glenmark has secured final approval by the United States Food & Drug Administration (US FDA) for Esomeprazole Magnesium Delayed-Release Capsules.

Glenmark | 15/06/2024 | By Aishwarya |  290

Glenmark Signs Exclusive Marketing and Distribution Deal with BeiGene

Glenmark has signed an exclusive marketing and distribution agreement with BeiGene, a global oncology company.

Glenmark | 21/05/2024 | By Aishwarya |  811

Glenmark, Strides Pharma, Cipla recalls products in US

The products were recalled due to manufacturing issues

Glenmark | 22/08/2022 | By Sudeep Soparkar |  1130